Selective targeting of muscarinic receptors: Novel therapeutic approaches for psychotic disorders

Current Neuropharmacology

Volumn 3, Issue 1, 2005, Pages 63-71

  Sur, Cyrille ^a   Kinney, Gene G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; CLOZAPINE; ESTERASE INHIBITOR; HALOPERIDOL; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; OXOTREMORINE; PHYSOSTIGMINE; RECEPTOR SUBTYPE; RIVASTIGMINE; TACRINE; XANOMELINE;

ALZHEIMER DISEASE; BRADYCARDIA; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; NEUROTRANSMISSION; NONHUMAN; PSYCHOSIS; REVIEW; SALIVARY GLAND DISEASE; SCHIZOPHRENIA; SWEAT GLAND DISEASE;

EID: 13844257170     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159052773413     Document Type: Review

References (77)

1. American Psychiatric Association, Diagnostic, Statistical Manual of MentalDisorders, Fourth Edition (DSM-IV), American Psychiatry Press, Washington, DC, (1994).
2. Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., Silva, A. J. (2003) Selective cognitive dysfunction inacetylcholine M1 muscarinic receptor mutant mice. Nature Neurosci., 6, 51-58.
3. Andersen, M. B., Fink-Jensen, A., Peacock, L., Gerlach, J., Bymaster, F., Lundbaek, J. A., Werge, T. (2003) The muscarinic M-1/M-4 receptor agonist-xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology, 28, 1168-1175.
4. Andreasen, N. (2000) Schizophrenia: the fundamental questions. Brain Res. Rev.. 31, 106-112.
5. Basile, A. S., Fedorova, I., Zapata, A., Liu, X., Shippenberg, T., Duttaroy, A., Yamada, M., Wess, J. (2002) Deletion of the M5 muscarinic acetyl-cholinereceptor attenuates morphine reinforce-ment, withdrawal but not morphineanalgesia. Proc. Natl. Acad. Sci. USA, 99, 11452-11457.
6. Beatty, W. W., Bierley, R. A. (1986) Scopolamine impairs encoding,retrieval of spatial working memory in rats. Physiol. Psychol.. 14, 82-86.
7. Bernard, V., Normand, E, Bloch, B. (1992) Phenotypical characteri-zation of therat striatal neurons expressing muscarinic receptor genes. J. Neurosci., 12, 3591-3600.
8. Birdsall, N.J.M., Farries, T., Gharagozloo, P., Kobayashi, S., Kuonen, D., Lazareno, S., Popham, A., Sugimoto, M. (1997) Selective allosteric enhancement of thebinding, actions of acetylcholine at muscarinic receptor subtypres. Life Sci., 60, 1047-1052.
9. Birdsall, N.J.M., Farries, T., Gharagozloo, P., Kobayashi, S., Lazareno, S., Sugimoto, M. (1999) Subtype-selective positive cooperative interactions between brucineanalogs, acetylcholine at muscarinic receptors: functional studies. Mol. Pharmacol., 55 778-786.
10. Birdsall, N.J.M., Nathanson, N.M., Schwarz, R.D. (2001) Muscarinic receptors:it's a knockout. Trends in Pharmacol. Sci., 22: 215-219.
11. Bleuler, E. (1911) Dementia Praecox or the group of schizo-phrenias. InternationalUniversity Press, New York.
12. Bodick, N.C., Offen, W.W., Levey, A.I., Cutler, N.R., Gauthier, S.G., Satlin, A., Shannon, H.E., Tollefson, G.D., Rasmusen, K., Bymaster, F.P., Hurley, D.J., Potter, W.Z., Paul, S.M. (1997) Effects of xanomeline, a selective muscarinic receptoragonist, on cognitive function, behavioral symptoms in Alzheimer disease. Arch. Neurology 54, 465-473.
13. Bodick, N.C., Offen, W.W., Shannon, H.E., Satterwhite, J., Lucas, R., van Lier, R., Paul, S.M. (1997) The selective muscarinic agonist xanomeline improves boththe cognitive deficits, behavioral symptoms of Alzheimer disease. AlzheimerDisease, Associated Disorders 11, 16-22.
14. Bonner, T.I., Buckley, N.J., Young, A.C., Brann, M.R. (1987) Identification of afamily of muscarinic acetylcholine receptor genes. Science, 237, 527-532.
15. Bonner, T.I., Young, A.C., Brann, M.R., Buckley, N.J. (1988) Cloning,expression of the human, rat m5 muscarinic receptor gene. Neuron, 1, 403-410.
16. Bullock, R., Cameron, A. (2002) Rivastigmine for the treatment of dementia,visual hallucinations associated with parkinson's disease: a case series. Curr. Med. Res. Opin., 18, 258-264.
17. Bymaster, F.P., Wong, D.T., Mitch, C.H., Ward, J.S., Calligaro, D.O., Schoepp, D.D., Shannon, H.E., Sheardown, M.J., Olesen, P.H., Suzdak, P.D., Swedberg, M.D.B., Sauerberg, P (1994) Neurochemical effects of the M1 muscarinic agonistxanomeline (Ly246708/NCC11-0232). J. Pharm. Exp. Ther., 289, 282-289.
18. Bymaster, F.P., Shannon, H.E., Rasmussen, K., DeLapp, N.W., Ward, J.S., Calligaro, D.O., Mitch, C.H., Whitesitt, C., Ludvigsen, T.S., Sheardown, M., Swedberg, M., Rasmussen, T., Olesen, P.H., Jeppesen, L., Sauerberg, A., Fink-Jensen, A. (1999) Potential role of muscarinic receptors in schizophrenia. LifeSci., 64, 527-534.
19. Bymaster, F.P., McKinzie, D.L., Felder, C.C., Wess, J. (2003) Use of M1-M5muscarinic receptor knockout mice as novel tools to delineate the physiologicalroles of the muscarinic cholinergic system. Neurochem. Res., 28, 437-442.
20. Carlsson, A., Hansson, L.O., Waters, N., Carlsson, M.L. (1997) Neurotransmitteraberrations in schizophrenia: new perspective, therapeutic implications. Life Sci., 61, 75-94.
21. Caulfield, M. P. (1993) Muscarinic receptors-characterization, coupling,function. Pharmacol Ther., 58, 319-379.
22. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors:noveltargets for drug discovery. Nature Drug Discovery, 1, 198-210.
23. DeLuca, V., Wang, H., Squassina, A., Wong, G.H.W., Yeomans, J., Kennedy, J.L. (2004) Linkage of M5 muscarinic, alpha 7-nicotinic receptor genes on15q13 to schizophrenia. Neuropsycho-Biology, 50 124-127.
24. Di Chiara, G., Morelli, M., Consolo, S. (1994) Modulatory functions ofneurotransmitters in the striatum: Ach/dopamine/NMDA interac-tions. Trends Neurosci., 17, 228-233.
25. Eglen, R.M., Choppin, A., Watson, N. (2001) Therapeutic oppor-tunities frommuscarinic receptor research. Trends Pharmacol. Sci., 22, 409-414.
26. Felder, C.C., Bymaster, F.P., Ward, J., DeLapp, N. (2000) Therapeuticopportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43, 4333-4353.
27. Felder, C.C., Porter, A.C., Skillman, T.L., Zhang, L., Bymaster, F.P., Nathanson, N.M., Hamilton, S.E., Gomeza, J., Wess, J., McKinzie, D.L. (2001) Elucidatingthe role of muscarinic receptors in psychosis. Life Sci., 68, 2605-2613.
28. Forster, G.L., Yeomans, J.S., Takeuchi, J., Blaha, C.D. (2002) M5 muscarinicreceptors are required for prolonged accumbal dopamine release after electricalstimulation of the pons in mice. J. Neurosci., 21, 1-6.
29. Gerber, D.J., Sotnikova, T.D., Gainetdinov, R.R., Huang, S.Y., Caron, M.G.,Tonegawa, S. (2001) Hyperactivity, elevated dopaminergic transmission,,response to amphetamine in M1 nuscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. USA, 98, 15312-15317.
30. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R. (2001)Pharmacological studies of prepulse inhibition models of sensorimotor gatingdeficits in schizophrenia: a decade in review. Psychopharmacology, 156, 117-154.
31. Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H., Wess, J. (1999) Pronounced pharmacologic deficits inM2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad Sci. USA, 96, 1692-1697.
32. Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C.X., Wess, J. (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptorknockout mice. Proc. Natl. Acad. Sci. USA, 96, 10483-10488.
33. Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Duttaroy, A., Deng, C.X., Wess, J. (2001) Generation and pharmacological analysis of m2, M4 muscarinic receptor knockout mice. Life Sci., 68, 2457-2466.
34. Hall, R.C., Popkin, M.K., Mchenry, L.E. (1977) Angel's Trumpet psychosis: acentral nervous system anticholinergic syndrome. Am. J. Psychiatry, 134, 312-314.
35. Hamilton, S.E., Loose, M.D., Qi, M., Levey, A.I., Hille, B., McKnight, G.S., Idzerda, R.L., Nathanson, N.M. (1997) Disruption of the m1 receptor gene ablatesmuscarinic receptor-dependent M current regulation, seizure activity in mice. Proc. Natl. Acad. Sci. USA, 94, 13311-13316.
36. Hamilton, S.E., Nathanson, N.M. (2001) The M1 receptor is required formuscarinic activation of mitogen-activated protein (MAP) kinase in murine-cerebral cortical neurons. Proc. Natl. Acad Sci. USA 276, 15850-15853.
37. Hardouin, S.N., Richmond, K.N., Zimmerman, A., Hamilton, S.E., Feigl, E.O., Nathanson, N.M. (2002) Altered cardiovascular responses in mice lacking the M1 muscarinic acetylcholine receptor. J. Pharm. Exp. Ther., 301, 129-137.
38. Hulme, E.C., Birdsall, N.J.M., Buckley, N.J. (1990) Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol., 30 633-673.
39. Hutchinson, M., Fazzini, E. (1996) Cholinesterase inhibition in Parkinson'sdisease. J. Neurol Neurosurg. Psychiatry, 61, 324-325.
40. Jones, C.K., Shannon, H.E. (2000) Muscarinic cholinergic modulation of prepulseinhibition of the acoustic startle reflex. J. Pharm. Exp. Ther., 294, 1017-1023.
41. Karasawa, H., Taketo, M.M., Matsui,M. (2003) Loss of anti-cataleptic effect ofscopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. Eur. J. Pharmacol., 468, 15-19.
42. Kaufer, D. (1998) Beyond the cholinergic hypothesis: the effect of metrifonateand other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 9, 8-14.
43. Kraepelin, E., Barclay, R.M., Robertson, G.M. (1919) Dementia Praecox, Paraphrenia. E., S. Livingstone, Edinburgh.
44. Krejci, A., Tucek, S. (2002) Quantitation of mRNAs for M1 to M5 subtypes ofmuscarinic receptors in rat heart, brain cortex. Mol. Pharmacol., 61, 1267-1272.
45. Lazareno, S., Gharagozloo, P., Kuonen, D., Popham, A., Birdsall, N.J.M. (1998) Subtype-selective positive cooperative interactions between brucine analogues- and acetylcholine at musca-rinic receptors: radioligand binding studies. Mol. Pharmacol., 53, 573-589.
46. Levey, A.I., Kitt, C.A., Simonds, W F., Price, D., Brann, M.R. (1991) Identification, localization of muscarinic acetylcholine receptor proteins inbrain with subtype-specific antibodies. J. Neurosci., 11, 3218-3226.
47. Marino, M.J., Rouse, S.T., Levey, A.I., Potter, L.T., Conn, P.J. (1998) Activation ofthe genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. USA, 95, 11465-11470.
48. Matsui, M., Motomura, D., Karasawa, H., Fujikawa, T., Jiang, J., Komiya, Y., Takahashi, S.I., Taketo, M.M. (2000) Multiple functional defects in peripheralautonomic organs in mice lacking muscarinic acetylcholine receptor gene for theM3 subtype. Proc. Natl. Acad. Sci. USA, 97, 9579-9584.
49. Matsui, M., Motomura, D., Fujikawa, T., Jiang, J., Takahashi, S.I., Manabe, T., Taketo, M.M. (2002) Mice lacking M2, M3 muscarinic acetylcholine-receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci., 22, 10627-10632.
50. 1, muscarinicacetylcholine receptor. J. Neurosci., 21, 5239-5250.
51. Neubauer, H., Sundland, D.M., Gershon, S. (1966) Ditran, its antagonists in amixed psychiatric population. J. Nerv. Ment. Dis., 142, 265-277.
52. Porter, A.C., Bymaster, F.P., DeLapp, N.W., Yamada, M., Wess, J., Hamilton, S.E., Nathanson, N.M., Felder, C.C. (2002) M1 muscarinic receptor signaling inmouse hippocampus, cortex. Brain Res., 944 82-89.
53. Rasmussen, T., Fink-Jensen, A., Sauerberg, P., Swedberg, M.D.B., Thomsen, C., Sheardown, M.J., Jeppesen, L., Calligaro, D.O., DeLapp, N.W., Whitesitt, C., Ward, J.S., Shannon, H.E., Bymaster, F.P. (2001) The muscarinic receptor agonistBuTAC, a novel potential antipsychotic, does not impair learning, memory inmouse passive avoidance. Schizophrenia Res., 49, 193-201.
54. Rosler, M. (2002) The efficacy of cholinesterase inhibitors in treating thebehavioural symptoms of dementia. Int. J. Clin. Pract. Suppl., 127, 20-36.
55. Rouse, S.T., Marino, M.J., Potter, L.T., Conn, P.J., Levey, A.I. (1999) Muscarinicreceptor subtypes involved in hippocampal circuits. Life Sci., 64, 501-509.
56. Samuel, W., Caligiuri, M., Galasko, D., Lacro, J., Marini, M., McClure, F.S., Warren, K., Jeste, D.V. (2000) Better cognitive, psychopathologic response todonepezil in patients prospectively diagnosed as dementia with Lewy bodies: apreliminary study. Int. J. Geriatr. Psychiatry, 15, 794-802.
57. Seeman, P. (1992) Dopamine receptor sequences. Therapeutic levels ofneuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacol, 7, 261-284.
58. Shannon, H.E., Bemis, K.G., Hendrix, J.C., Ward, J.S. (1990) Interactionsbetween scopolamine, muscarinic cholinergic ago-nists or cholinesteraseinhibitors on spatial alternation performance in rats. J. Pharm. Exp. Ther., 255, 1071-1077.
59. Shannon, H.E., Hart, J.C., Bymaster, F.P., Calligaro, D.O., Delapp, N.W., Mitch, C.H., Ward, J.S., Fink-Jensen, A., Sauerberg, p., Jeppesen, L., Sheardown, M. J., Swedberg, M. D. B. (1999) Muscarinic receptor agonists, like dopamine receptorantagonist antipsychotics, inhibit conditioned avoidance response in rats. J. Pharm. Exp. Ther. 290, 901-907.
60. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D.B., Jeppesen, L., Sheardown, M.J., Sauerberg, P., Fink-Jensen, A. (2000) Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats, mice. Schizophrenia Res., 42, 249-259.
61. Shekhar, A., Potter, W.Z., Lienemann, J., Sundblad, K., Lightfoot, J., Herrera, J., Unverzagt, F., Bymaster, F.P., Felder, C.C. (2003) Efficacy of xanomeline, aselective muscarinic agonist, in treating schizophrenia: A double-blind, placebocontrolled study. Am. Coll. NeuroPsychopharmacology Meeeting, pp. 135, 173.
62. Sing, M.M.,Kay, S.R. (1975) Therapeutic reversal with benxtropine inschizophrenics. Practical, theoretical significance. J. Nerv. Ment. Dis., 160, 258-266.
63. Sing, M.M., Kay, S.R. (1979) Therapeutic antagonism between anticholinergicantiparkinsonism agents, neuropleptics in schizophrenia. Implications for aneuropharmacological model. Neuropsychobiology, 5, 74-86.
64. 1 muscarinic receptor. Mol. Pharmacol., 61, 1297-1302.
65. Stanhope, K.J., Mirza, N.R., Bickerdike, M.J., Bright, J.L., Harrington, N.R., Hesselink, M.B., Kennett, G.A., Lightowler, S., Sheardown, M.J., Syed, R., Upton, R.L., Wadsworth, G., Weiss, S.M., Wyatt, A. (2001) The muscarinicreceptor agonist xanomeline has an antipsychotic-like profile in rat. J. Pharmacol. Exp. Ther., 299 782-792.
66. Stengel, P.W., Yamada, M., Wess, J., Cohen, M.L. (2002) M3-receptor knockoutmice: muscarinic receptor function in atria, stomach fundus, urinary bladder,,trachea. Am. J. Physiol. Regulatory Integrative Comp. Physiol., 282, 1443-1449.
67. Sur, C., Mallorga, P.J., Wittmann, M., Jacobson, M.A., Pascarella, D., Williams, J.B., Brandish, P.E., Pettibone, D.J., Scolnick, E.M., Conn, P.J. (2003) N-desmethylclcozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. USA, 100, 13674-13679.
68. Tzavara, E.T., Bymaster, F.P., Davis, R.J., Wade, M.R., Perry, K.W., Wess, J., McKinzie, D.L., Felder, C., Nomikos, G.G. (2004) M4 muscarinic receptors-regulate the dynamics of cholinergic, dopaminergic neurotransmission:relevance to the pathophysiology, treatment of related central nervous systempathologies. FASEB J., 7, 1-18.
69. Vilaro, M.T., Palacios, J.M., Mengod, G. (1990) Localization of m5 muscarinicreceptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett., 114, 154-159.
70. Wang, H., Ng, K., Hayes, D., Gao, X., Forster, G., Blaha, C., Yeomans, J. (2004) Decreased amphetamine-induced locomotion, improved latent inhibition inmice mutant for the M5 muscarinic receptor gene found in the human 15qschizophrenia region. Neuropsychopharmacology, 6 1-14.
71. Weiner, D.M., Meltzer, H.Y., Veinbergs, I., Donohue, E.M., Spalding, T.A., Smith, T.T., Mohell, N., Harvey, S.C., Lameh, J., Nash, N., Vanover, K.E., Olsson, R., Jayathilake, K., Lee, M., Levey, A.I., Hacksell, U., Burstein, E.S., Davis, R.E., Brann, M.R. (2004) The role of M1 muscarinic receptor agonism ofN-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology, Online 16 July (2004).
72. Wess, J. (2004) Muscarinic acetylcholine receptor knockout mice: novelphenotypes, clinical implications. Annu. Rev. Pharmacol. Toxicol., 44, 423-450.
73. Wood, M.D., Murkitt, K.L., Ho, M., Watson, J.M., Brown, F., Hunter, A.J., Middlemiss, D.N. (1999) Functional comparison of muscarinic partial agonists atmuscarinic receptor subtypes hM1, hM2, hM3, hM4, hM5 usingmicrophysiometry. Br. J. Pharmacol. 126, 1620-1624.
74. Woolf, N.J. (1991) Cholinergic systems in mammalian brain, spinal cord. Prog. Neurobiol., 37, 475-524.
75. Yamada, M., Lamping, K.G., Duttaroy, A., Zhang, W., Cui, Y., Bymaster, F.P., McKinzie, D.L., Felder, C.C., Deng, C.X., Faraci, F.M., Wess, J. (2001)Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinicacetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA, 98, 14096-14101.
76. Yeomans, J.S. (1995) Role of tegmental cholinergic neurons in dopaminergicactivation, antimuscarinic psychosis, schizophrenia. Neuropsychopharmacology, 12, 3-16.
77. Zhang, W., Basile, A.S., Gomeza, J., Volpicelli, L.A., Levey, A.I., Wess, J. (2002) Characterization of central inhibitory muscarinic autoreceptors by the useof muscarinic acetylcholine receptor knock-out mice. J. Neurosci., 22, 1709-1717.